Advanced Endometrial Cancer: Treatment Optimization - Episode 14

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

January 13, 2023

Courtney R. Arn, APRN-CNP, Kimberly Halla, NP, Kathleen Lutz, RN, NP-BC WH, Kimberly A. Spickes, CNP

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

EP. 1: Symptoms and Diagnosis of Endometrial Cancer

EP. 2: Initial Consultation of Patients With Advanced Endometrial Cancer

EP. 3: Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis

EP. 4: Resources for Patients With Endometrial Cancer

EP. 5: Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

EP. 6: Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

EP. 7: Currently Available Treatment Modalities in Endometrial Cancer

EP. 8: First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

EP. 9: Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

EP. 10: Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

EP. 11: Treatment Options for Patients with Recurrent Endometrial Cancer

EP. 12: Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

EP. 13: Monitoring Patients on Therapy for Recurrent Endometrial Cancer

Now Viewing

EP. 14: Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

EP. 15: Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

EP. 16: Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

EP. 17: Greatest Unmet Needs for Patients with Endometrial Cancer

EP. 18: Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer